| Name | Title | Contact Details |
|---|
We re committed to breakthrough firsts in womens sexual health. Novel ideas fuel our entrepreneurial passion. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we re trying to collectively accomplish.
The Warner Babcock Institute for Green Chemistry is dedicated to the development of non toxic, environmentally benign and sustainable technological solutions for society. Focused on the practical application of Green Chemistry, we assist our industry partners in the development of sustainable technologies, products, and processes at the molecular level. Our emphasis is on the practical application of Green Chemistry concepts to drive cost savings and minimize time to market. The Warner Babcock Institute for Green Chemistry was founded in 2007 by Dr. John C. Warner, one of the founders of the field and co-author of seminal book Green Chemistry: Theory and Practice, which first defined the Twelve Principles of Green Chemistry.
SAFECOR HEALTH LLC is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Mesa, AZ. To find more information about SAFECOR HEALTH LLC, please visit www.safecorhealth.com
Advanced Biomedical Research is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."